(NASDAQ: NVAX) Novavax's forecast annual revenue growth rate of -38.19% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 89.41%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 11.75%.
Novavax's revenue in 2025 is $1,078,718,000.On average, 4 Wall Street analysts forecast NVAX's revenue for 2025 to be $170,213,823,419, with the lowest NVAX revenue forecast at $167,315,409,164, and the highest NVAX revenue forecast at $173,774,917,986. On average, 4 Wall Street analysts forecast NVAX's revenue for 2026 to be $57,629,960,814, with the lowest NVAX revenue forecast at $52,666,842,608, and the highest NVAX revenue forecast at $67,388,740,511.
In 2027, NVAX is forecast to generate $60,634,436,403 in revenue, with the lowest revenue forecast at $55,051,192,356 and the highest revenue forecast at $64,458,654,035.